Perception of the COVID-19 Pandemic in Patients With Haematological or Solid Neoplasias

Study Overview
=================
Brief Summary
-----------------
Cancer patients are among the most vulnerable individuals, whose health-related quality of life (HRQOL) may be substantially impacted by the COVID19 pandemic. We want to study how the COVID-19 pandemic influences the life of cancer patients and how these patients cope with the additional distress with the aim to facilitate the development of improved future interventional strategies to maintain resilience and HRQOL

Detailed Description
-----------------
In December 2019, the novel human pathogenic virus SARS-CoV2 from the coronavirus family was identified, causing a respiratory disease known as COVID19 (coronavirus disease 2019). COVID19 manifests itself primarily with influenza-like symptoms, but in special cases it can lead to severe conditions such as ARDS (acute respiratory distress syndrome). Compared to other pulmotropic viruses such as the influenza virus, SARS-CoV-2 is associated with a higher contagiousness and mortality. Haematological and oncological patients are particularly vulnerable due to their advanced age, immunological restrictions in the context of the underlying disease and the treatment modalities (chemotherapy, radiation therapy, ...). To evaluate the effects of the COVID19 pandemic on the perception of patients with malignant diseases, we aim to record so-called patient-reported outcomes (PROs) from patients at the University Hospital of Innsbruck at the Department of Internal Medicine V (Hematology and Oncology) and at the Department for Radiotherapy and Radiation Oncology. We use the validated EORT QLQ-C30 and a specially developed questionnaire for COVID19.

Official Title
-----------------
Investigation of the Perception of the COVID-19 Pandemic in Patients With Haematological or Solid Neoplasias Using Patient-reported Outcome Measures (PROMs)

Conditions
-----------------
Covid19

Intervention / Treatment
-----------------
* Other: questionnaire


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age > 18 years validated hematological or oncological disease informed consent Exclusion Criteria: Age < 18 years Insufficient discernment

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| cancer patients<br>adult cancer patients, with solid or hematologic malignancies, neither tested positive nor having COVID19 symptoms | Other: questionnaire<br>* 13-item questionnaire about cancer patient's distress and everyday life, EORTC-QLQ-C30<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Influence of the COVID-19 pandemic on cancer patient's daily life | evaluation via questionnaire | single time | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
SARS-CoV-2, COVID19 pandemic, cancer patients, distress, HRQOL